Louisiana Hematology Oncology Associates LLC

Summary

Louisiana Hematology Oncology Associates LLC is a medical facility located in Baton Rouge, Louisiana. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Cancer, Colorectal Cancer and other specialties. Louisiana Hematology Oncology Associates LLC is involved with conducting 88 clinical trials across 134 conditions. There are 4 research doctors associated with this hospital, such as David S. Hanson, Victor T. Lin, Augusto C. Ochoa, and William T. Varnado.

Top PIs

Clinical Trials running at Louisiana Hematology Oncology Associates LLC

Bladder Cancer

Breast Cancer

Breast cancer

Lung Cancer

Pancreatic Cancer

Cancer

Prostate Cancer

Colorectal Cancer

Pancreatic Carcinoma

Kidney Cancer

Eribulin + Chemotherapy

for Bladder Cancer

This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.

Recruiting

2 awards

Phase 3

Blood Sample Collection

for Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

Recruiting

1 award

N/A

9 criteria

Pembrolizumab + Radiation

for Bladder Cancer

This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving pembrolizumab with radiation may kill more tumor cells than chemotherapy with radiation therapy in patients with non-muscle invasive bladder cancer.

Recruiting

1 award

Phase 2

9 criteria